Mesoblast (MESO) Net Cash Flow (2014 - 2023)
Mesoblast (MESO) posted Net Cash Flow of $22.5 million for Q2 2023, up 219.88% sequentially from -$18.8 million in Q1 2023, and up 239.23% YoY from $6.6 million in Q2 2022.
Analysis
Mesoblast (MESO) Net Cash Flow (2014 - 2023) Analysis & Trends
Mesoblast has reported Net Cash Flow for 8 years, with the latest figure at $22.5 million in Q2 2023.
- Quarterly Net Cash Flow rose 239.23% year-over-year to $22.5 million in Q2 2023, while the trailing twelve-month figure through Dec 2024 was $22.5 million (up 252.31% YoY) and the FY2025 annual result came in at $97.5 million, up 1273.74% from the prior year.
- Net Cash Flow grew to $22.5 million in Q2 2023 per MESO's latest filing, from -$18.8 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $81.0 million in Q1 2021 and troughed at -$31.7 million in Q4 2020.
- A 5-year average of -$439500.0 and a median of -$18.3 million in 2022 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2020 and 2021: Net Cash Flow plunged 208.58% in 2020, then soared 491.98% in 2021.
- Over 5 years, Net Cash Flow stood at $46.4 million in 2019, then sank by 168.33% to -$31.7 million in 2020, then jumped by 33.25% to -$21.2 million in 2021, then rose by 12.66% to -$18.5 million in 2022, then soared by 221.59% to $22.5 million in 2023.
- According to Business Quant data, Net Cash Flow over the past three periods registered $22.5 million, -$18.8 million, and -$18.5 million for Q2 2023, Q1 2023, and Q4 2022 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -183.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 407.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -496,000.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 149.03 Mn |
| Mar 31, 2023 | -80.25 Mn |
| Dec 31, 2022 | 14.41 Mn |
| Sep 30, 2022 | 54.38 Mn |
| Jun 30, 2022 | -16.16 Mn |
| Mar 31, 2022 | -18.10 Mn |
| Dec 31, 2021 | -21.18 Mn |
| Sep 30, 2021 | 15.95 Mn |
| Jun 30, 2021 | -21.38 Mn |
| Mar 31, 2021 | 80.96 Mn |
| Dec 31, 2020 | -31.73 Mn |
| Sep 30, 2020 | -21.71 Mn |
| Mar 31, 2020 | 9.94 Mn |
| Dec 31, 2019 | 30.59 Mn |
| Sep 30, 2019 | -15.85 Mn |
| Mar 31, 2019 | -6.69 Mn |
| Dec 31, 2018 | 55.28 Mn |
| Sep 30, 2018 | 17.52 Mn |
| Jun 30, 2018 | -21.64 Mn |
| Mar 31, 2018 | 12.06 Mn |